A Double-blind, Placebo-controlled, Randomized Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function and Cardiovascular Risk in Patients With Early Vascular Disease

Trial Profile

A Double-blind, Placebo-controlled, Randomized Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function and Cardiovascular Risk in Patients With Early Vascular Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Mar 2017

At a glance

  • Drugs Nebivolol (Primary) ; Atenolol
  • Indications Hypertension; Vascular disorders
  • Focus Pharmacodynamics
  • Acronyms EVIDENCE
  • Most Recent Events

    • 23 Dec 2016 Status changed from active, no longer recruiting to completed according to results presented at the 89th Annual Scientific Sessions of the American Heart Association..
    • 16 Nov 2016 Primary endpoint of endothelial function (change in small artery elasticity) has been met, according to results presented at the 89th Annual Scientific Sessions of the American Heart Association.
    • 16 Nov 2016 Results presented at the 89th Annual Scientific Sessions of the American Heart Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top